Orbus gets $32.5M to repurpose hirsutism drug for brain cancer
Palo Alto startup Orbus Therapeutics just reeled in $32.5 million to bring eflornithine, an already-approved drug for hirsutism and sleeping sickness, into Phase 3 trials for brain cancer.